Skip to main content
Premium Trial:

Request an Annual Quote

MDS Pharma, Compendia to Develop Cancer PGx Platform

NEW YORK (GenomeWeb News) – MDS Pharma Services and Compendia Bioscience have collaborated to develop a pharmacogenomic platform for use in cancer patients and therapeutics research, MDS said today.

The new OncoPredictor combines MDS Pharma Services' OncoPanel, which offers high-content screening of up to 240 cancer cell lines for sensitivity to specific cancer drugs and drug combinations, with Compendia's Oncomine database. The Compendia database of cancer genomic profiles and its analysis application provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from 27,000 reference patients.

The combined OncoPredictor system will analyze drug sensitivity and resistance of novel drugs and drug combinations for cancer research.

"Our pharmaceutical and biotechnology clients seek to determine the efficacy of their compounds across cancer genotypes and patient phenotypes," Compendia's CEO Dan Rhodes said in a statement. "OncoPredictor will help provide the answer with technology for information-based lead selection, predictive in vivo study design and biomarker development."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.